TScan Therapeutics因暂停癌症临床试验而股价下跌

路透中文

Sep 02

BUZZ-TScan <a href="https://laohu8.com/S/LENZ">Therapeutics</a>因暂停癌症临床试验而股价下跌

9月2日 - ** 药物研发公司 TScan Therapeutics（TCRX.O）的股价在盘前交易中下跌 9.9%，至 60 美分

** TCRX暂停了实验性血液癌症疗法TSC-101的一项后期临床试验的患者招募，称缺乏完成该研究的资金

** 随着公司将重点转向针对实体瘤的实验性细胞疗法，该公司将为其血液癌症和自身免疫性疾病项目寻求合作伙伴

** 该公司计划于2027年第四季度启动两项实体瘤治疗方案的早期人体试验

** TCRX还将裁减约75%的员工，关闭内部生产运营并缩减研发活动

** 此次重组预计将在2027年前节省5,500万美元，并将现金储备维持至2027年第四季度

** 截至上一交易日收盘，TCRX今年迄今累计下跌33.4%

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2664196188"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2664196188\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2664196188?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-09-02 19:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2664196188","market":"hk","top_or_hot":-1,"title":"TScan Therapeutics因暂停癌症临床试验而股价下跌","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-TScan <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>因暂停癌症临床试验而股价下跌</title></head><body><p><span>9月2日</span><span> - </span>** 药物研发公司 TScan Therapeutics（<span>TCRX.O</span>）的股价在盘前交易中下跌 9.9%，至 60 美分</p><p>** TCRX暂停了实验性血液癌症疗法TSC-101的一项后期临床试验的患者招募，称缺乏完成该研究的资金</p><p>** 随着公司将重点转向针对实体瘤的实验性细胞疗法，该公司将为其血液癌症和自身免疫性疾病项目寻求合作伙伴</p><p>** 该公司计划于2027年第四季度启动两项实体瘤治疗方案的早期人体试验</p><p>** TCRX还将裁减约75%的员工，关闭内部生产运营并缩减研发活动</p><p>** 此次重组预计将在2027年前节省5,500万美元，并将现金储备维持至2027年第四季度</p><p>** 截至上一交易日收盘，TCRX今年迄今累计下跌33.4%</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TScan Therapeutics因暂停癌症临床试验而股价下跌</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTScan Therapeutics因暂停癌症临床试验而股价下跌\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time\">2026-09-02 19:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-TScan <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>因暂停癌症临床试验而股价下跌</title></head><body><p><span>9月2日</span><span> - </span>** 药物研发公司 TScan Therapeutics（<span>TCRX.O</span>）的股价在盘前交易中下跌 9.9%，至 60 美分</p><p>** TCRX暂停了实验性血液癌症疗法TSC-101的一项后期临床试验的患者招募，称缺乏完成该研究的资金</p><p>** 随着公司将重点转向针对实体瘤的实验性细胞疗法，该公司将为其血液癌症和自身免疫性疾病项目寻求合作伙伴</p><p>** 该公司计划于2027年第四季度启动两项实体瘤治疗方案的早期人体试验</p><p>** TCRX还将裁减约75%的员工，关闭内部生产运营并缩减研发活动</p><p>** 此次重组预计将在2027年前节省5,500万美元，并将现金储备维持至2027年第四季度</p><p>** 截至上一交易日收盘，TCRX今年迄今累计下跌33.4%</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nL4T44U11H:1","article_id":"2664196188","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2664196188","pubTimestamp":1788350122,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-TScan Therapeutics因暂停癌症临床试验而股价下跌9月2日-** 药物研发公司 TScan Therapeutics（TCRX.O）的股价在盘前交易中下跌 9.9%，至 60 美分** TCRX暂停了实验性血液癌症疗法TSC-101的一项后期临床试验的患者招募，称缺乏完成该研究的资金** 随着公司将重点转向针对实体瘤的实验性细胞疗法，该公司将为其血液癌症和自身免疫性疾病项目","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4139":"生物科技","TCRX":"Tscan Therapeutics, Inc.","BK4539":"次新股"},"translate_title":"TScan Therapeutics shares fell due to the suspension of cancer clinical trials","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TCRX":0.9},"content_text":"BUZZ-TScan <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>因暂停癌症临床试验而股价下跌9月2日 - ** 药物研发公司 TScan Therapeutics（TCRX.O）的股价在盘前交易中下跌 9.9%，至 60 美分** TCRX暂停了实验性血液癌症疗法TSC-101的一项后期临床试验的患者招募，称缺乏完成该研究的资金** 随着公司将重点转向针对实体瘤的实验性细胞疗法，该公司将为其血液癌症和自身免疫性疾病项目寻求合作伙伴** 该公司计划于2027年第四季度启动两项实体瘤治疗方案的早期人体试验** TCRX还将裁减约75%的员工，关闭内部生产运营并缩减研发活动** 此次重组预计将在2027年前节省5,500万美元，并将现金储备维持至2027年第四季度** 截至上一交易日收盘，TCRX今年迄今累计下跌33.4%","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}